Hair loss in women is more common than the conversation around it suggests, and the patterns are different enough from male-pattern hair loss that the standard male-focused messaging is often unhelpful. A widening centre parting, a fuller hairbrush, a low ponytail that used to be twice the thickness — these are the observations that usually bring women to a consultation, and they can have a range of causes. Some are entirely reversible.

This guide walks through the main patterns and drivers, the blood tests a clinician usually considers, and the treatment options available in the UK. It is not a substitute for a personal assessment, but it should give you a clearer picture of what a clinician is likely to think about.

The two most common patterns

Two conditions account for most hair loss in women, and telling them apart matters because the treatment differs.

Female-pattern hair loss

Female-pattern hair loss (also called female androgenetic alopecia) is a genetic tendency towards gradual thinning of hair over the top of the scalp. Unlike men, women rarely lose the frontal hairline — the classic sign is a widening of the centre parting and reduced density on the crown, with the front held relatively intact. It usually comes on slowly over years, sometimes accelerating around perimenopause. Family history on either side of the family is a common thread.

Telogen effluvium

Telogen effluvium is a diffuse shed rather than a pattern. Normally, most hairs sit in the growth (anagen) phase while a smaller proportion cycle through the shedding (telogen) phase. A shock to the system pushes an unusually large number of follicles into telogen at once — and around two to three months later, they all shed together. The result is noticeable thinning, often described as handfuls of hair coming out in the shower.

The triggers are familiar: a severe illness or high fever, major surgery, sudden weight loss or dietary restriction, significant psychological stress, starting or stopping certain medications, and — very commonly — pregnancy. The reassuring point is that telogen effluvium is usually self-limiting. Once the trigger passes, the hair cycle rebalances over the following six to twelve months, and density typically returns.

Postpartum hair loss

Postpartum shedding is the most predictable telogen effluvium. During pregnancy, elevated oestrogen keeps more hairs in the growth phase for longer, giving many women unusually thick hair. After delivery, hormone levels normalise, and the delayed shed catches up all at once — often two to four months after giving birth. It can look dramatic. In most cases it settles within a year, and the underlying density returns to the pre-pregnancy baseline. Persistent thinning beyond twelve months, or thinning that follows a female-pattern distribution, warrants review.

Reversible medical causes worth checking

Some medical conditions cause hair thinning as one of their signals, and are worth ruling in or out before assuming a pattern condition.

  • Thyroid disease. Both underactive and overactive thyroid can cause diffuse hair loss. Other symptoms — fatigue, weight change, temperature intolerance, cycle changes — often accompany the hair change. Thyroid function tests are a standard first check.
  • Iron deficiency. Low iron stores, measured by ferritin, are strongly linked to hair shedding in women, particularly with heavy periods, restrictive diets, or after pregnancy. Restoring iron levels takes months, and hair follows on a slower timeline than the blood picture.
  • PCOS and hormonal drivers. Polycystic ovary syndrome can produce a mixed picture — hair thinning on the scalp alongside unwanted hair elsewhere, cycle irregularity, and acne. If a clinician suspects a hormonal driver they will consider relevant bloods and, where appropriate, refer for specialist input.
  • Perimenopause and menopause. Falling oestrogen and shifting androgen balance can unmask a genetic tendency to female-pattern hair loss around this life stage. A hair change here is often part of a broader menopause picture.
  • Medication effects. A range of medications can contribute, including some anticoagulants, beta blockers, retinoids, and hormonal treatments. A clinician will review your full medication list.

Sudden patchy loss (round bald patches) or hair loss with scalp symptoms — pain, redness, scarring, itching — is a different clinical picture and needs prompt review rather than a topical trial.

How female-pattern hair loss is treated

Once reversible causes are addressed and a pattern picture is confirmed, several treatment options exist. The general aim is to slow further miniaturisation of follicles and, where possible, encourage some regrowth. Response is gradual, and continuing treatment maintains the benefit.

Topical minoxidil

Topical minoxidil is the most established treatment for female-pattern hair loss in the UK. Applied to the scalp daily, it works by prolonging the growth phase of the hair cycle and stimulating follicles that have started to miniaturise. Response typically takes three to six months to become visible and reaches its peak around twelve months. Treatment needs to be continued for the benefit to be maintained — stopping usually leads to a gradual return to the untreated trajectory over the following months.

Side effects are usually mild — most commonly scalp dryness or irritation at the application site. Some women notice an initial shed in the first few weeks, which is disconcerting but is a recognised transitional effect rather than a sign the treatment is not working.

Other options a clinician may consider

Beyond topical minoxidil, several other options may come up depending on your presentation, preferences and medical history.

  • Low-dose oral minoxidil. Used off-licence in the UK for some women when topical minoxidil is not tolerated, not effective enough, or not practical. It is a specialist-led decision with dose titration and monitoring.
  • Spironolactone. A diuretic with anti-androgen activity, prescribed off-licence for female-pattern hair loss in selected women, particularly where there is a hormonal component. It requires monitoring and has specific contraindications.
  • Finasteride. Used in men for pattern hair loss (see our guide to finasteride dosing), finasteride is occasionally used off-licence in postmenopausal women under specialist supervision. It is not appropriate for anyone who could become pregnant, because of a risk of harm to a male foetus.
  • Combined hormonal contraception. Where hormonal drivers are relevant, a specific combined pill may be considered as part of the picture. This is a clinical judgement that weighs several factors.
  • Managing the underlying condition. Treating an underactive thyroid, correcting iron deficiency, or managing PCOS as a whole often produces more meaningful improvement than a hair-specific treatment on its own.

How this differs from the male-pattern approach

The male-pattern conversation usually orbits around finasteride and topical minoxidil, targeting DHT-driven miniaturisation on the crown and hairline. In women, the picture is broader. Female-pattern hair loss is more heterogeneous in its drivers, telogen effluvium is a much more common overlay, and reversible medical causes carry more weight in the assessment. Treatment tends to combine an underlying-cause review with a topical option first, and specialist-led alternatives if response is inadequate. Direct extrapolation from a male-pattern guide can be misleading — the tests, the shortlist and the expected timelines are not the same.

Realistic timelines and follow-up

Hair moves slowly. Whichever route is chosen, the honest answer is that response is judged in months, not weeks. A pragmatic timeline looks something like this:

  • Weeks 0–6: establish the routine, tolerate any initial shed or scalp irritation, address any reversible cause identified on bloods.
  • Months 3–6: the earliest point at which a clinician would call meaningful response. Reduced shedding usually comes before visible thickening.
  • Months 6–12: peak response for topical treatments. This is when a longer-term plan — continuing, combining or reassessing — is agreed.

Follow-up matters. A single starting point without review often leads to people quietly stopping treatment because they cannot tell whether it is working. A clinician can look at the trajectory objectively and adjust the plan.

What to bring to a consultation

A clinician will want to understand the pattern (widening parting versus diffuse shed versus patchy loss), the timeline, any trigger events, family history, cycle history, medications, and any accompanying symptoms. Recent bloods, if you have them, are useful. If you have noticed skin or other symptoms that could point to a hormonal picture — our overview on menopause and treatment pathways and the guide on HRT can be useful background if that stage of life is on your mind. A UK-registered clinician will use that picture to suggest a starting point, explain what to expect, and agree when to review.